Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 180

1.

CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.

Antony PA, Piccirillo CA, Akpinarli A, Finkelstein SE, Speiss PJ, Surman DR, Palmer DC, Chan CC, Klebanoff CA, Overwijk WW, Rosenberg SA, Restifo NP.

J Immunol. 2005 Mar 1;174(5):2591-601.

2.
3.

Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.

Jensen SM, Twitty CG, Maston LD, Antony PA, Lim M, Hu HM, Petrausch U, Restifo NP, Fox BA.

J Immunol. 2012 Jul 15;189(2):767-76. doi: 10.4049/jimmunol.1103822. Epub 2012 Jun 20.

4.

Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells.

Overwijk WW, Theoret MR, Finkelstein SE, Surman DR, de Jong LA, Vyth-Dreese FA, Dellemijn TA, Antony PA, Spiess PJ, Palmer DC, Heimann DM, Klebanoff CA, Yu Z, Hwang LN, Feigenbaum L, Kruisbeek AM, Rosenberg SA, Restifo NP.

J Exp Med. 2003 Aug 18;198(4):569-80.

5.

CD4+/CD25+ regulatory cells inhibit activation of tumor-primed CD4+ T cells with IFN-gamma-dependent antiangiogenic activity, as well as long-lasting tumor immunity elicited by peptide vaccination.

Casares N, Arribillaga L, Sarobe P, Dotor J, Lopez-Diaz de Cerio A, Melero I, Prieto J, BorrĂ¡s-Cuesta F, Lasarte JJ.

J Immunol. 2003 Dec 1;171(11):5931-9.

6.
7.

Effective induction of therapeutic antitumor immunity by dendritic cells coexpressing interleukin-18 and tumor antigen.

Xia D, Zheng S, Zhang W, He L, Wang Q, Pan J, Zhang L, Wang J, Cao X.

J Mol Med (Berl). 2003 Sep;81(9):585-96. Epub 2003 Aug 21.

PMID:
12937899
8.

Vaccine-stimulated, adoptively transferred CD8+ T cells traffic indiscriminately and ubiquitously while mediating specific tumor destruction.

Palmer DC, Balasubramaniam S, Hanada K, Wrzesinski C, Yu Z, Farid S, Theoret MR, Hwang LN, Klebanoff CA, Gattinoni L, Goldstein AL, Yang JC, Restifo NP.

J Immunol. 2004 Dec 15;173(12):7209-16.

10.

Targeted interleukin 2 therapy enhances protective immunity induced by an autologous oral DNA vaccine against murine melanoma.

Niethammer AG, Xiang R, Ruehlmann JM, Lode HN, Dolman CS, Gillies SD, Reisfeld RA.

Cancer Res. 2001 Aug 15;61(16):6178-84.

11.

In vivo cyclophosphamide and IL-2 treatment impedes self-antigen-induced effector CD4 cell tolerization: implications for adoptive immunotherapy.

Mihalyo MA, Doody AD, McAleer JP, Nowak EC, Long M, Yang Y, Adler AJ.

J Immunol. 2004 May 1;172(9):5338-45.

12.
13.

Tumor-specific CD4+ T cells maintain effector and memory tumor-specific CD8+ T cells.

Church SE, Jensen SM, Antony PA, Restifo NP, Fox BA.

Eur J Immunol. 2014 Jan;44(1):69-79. doi: 10.1002/eji.201343718. Epub 2013 Nov 21.

14.

Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance.

Antov A, Yang L, Vig M, Baltimore D, Van Parijs L.

J Immunol. 2003 Oct 1;171(7):3435-41.

15.

Interleukin-7-dependent expansion and persistence of melanoma-specific T cells in lymphodepleted mice lead to tumor regression and editing.

Wang LX, Li R, Yang G, Lim M, O'Hara A, Chu Y, Fox BA, Restifo NP, Urba WJ, Hu HM.

Cancer Res. 2005 Nov 15;65(22):10569-77.

16.

IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells.

Klebanoff CA, Finkelstein SE, Surman DR, Lichtman MK, Gattinoni L, Theoret MR, Grewal N, Spiess PJ, Antony PA, Palmer DC, Tagaya Y, Rosenberg SA, Waldmann TA, Restifo NP.

Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1969-74. Epub 2004 Feb 4.

17.

Agonist anti-GITR antibody enhances vaccine-induced CD8(+) T-cell responses and tumor immunity.

Cohen AD, Diab A, Perales MA, Wolchok JD, Rizzuto G, Merghoub T, Huggins D, Liu C, Turk MJ, Restifo NP, Sakaguchi S, Houghton AN.

Cancer Res. 2006 May 1;66(9):4904-12.

18.

Neuropilin 1 deficiency on CD4+Foxp3+ regulatory T cells impairs mouse melanoma growth.

Hansen W, Hutzler M, Abel S, Alter C, Stockmann C, Kliche S, Albert J, Sparwasser T, Sakaguchi S, Westendorf AM, Schadendorf D, Buer J, Helfrich I.

J Exp Med. 2012 Oct 22;209(11):2001-16. doi: 10.1084/jem.20111497. Epub 2012 Oct 8.

19.

Improved tumor immunity using anti-tyrosinase related protein-1 monoclonal antibody combined with DNA vaccines in murine melanoma.

Saenger YM, Li Y, Chiou KC, Chan B, Rizzuto G, Terzulli SL, Merghoub T, Houghton AN, Wolchok JD.

Cancer Res. 2008 Dec 1;68(23):9884-91. doi: 10.1158/0008-5472.CAN-08-2233.

20.
Items per page

Supplemental Content

Write to the Help Desk